[go: up one dir, main page]

MX2016009491A - Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. - Google Patents

Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.

Info

Publication number
MX2016009491A
MX2016009491A MX2016009491A MX2016009491A MX2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A
Authority
MX
Mexico
Prior art keywords
dpp4
antagonist
disorder
specific
biomarker
Prior art date
Application number
MX2016009491A
Other languages
English (en)
Inventor
Yao Yihong
Liang Meina
Streicher Katie
Ranade Koustubh
Vainshtein Inna
Piper Edward
May Richard
NORDENMARK Lars
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2016009491A publication Critical patent/MX2016009491A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)

Abstract

La presente invención se refiere al uso de DPP4 (por ejemplo, niveles de expresión de proteína o génicos) como biomarcador para enfermedades o trastornos mediados por IL-13, por ejemplo, asma, FPI, EPOC o dermatitis atópica. Los niveles del biomarcador DPP4 por encima o por debajo de un nivel umbral predeterminado de DPP4 pueden usarse, por ejemplo, (i) para determinar la elegibilidad de un paciente para un determinado tratamiento con un antagonista de IL-13, (ii) para determinar si un determinado tratamiento de una enfermedad o trastorno mediado por IL-13 con un antagonista de IL-13 debería comenzar, suspenderse o modificarse, (iii) para diagnosticar si una afección o trastorno mediado por IL-13 es tratable con un antagonista específico de IL-13, (iv) para pronosticar el resultado de tratar una enfermedad o trastorno mediado por IL-13 con un antagonista específico de IL-13, etc. La descripción proporciona además kits de ensayo para la detección de DPP4, así como para métodos diagnóstico implementados por ordenador.
MX2016009491A 2014-01-27 2015-01-26 Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. MX2016009491A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931878P 2014-01-27 2014-01-27
US201461990932P 2014-05-09 2014-05-09
PCT/US2015/012885 WO2015112970A1 (en) 2014-01-27 2015-01-26 Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung

Publications (1)

Publication Number Publication Date
MX2016009491A true MX2016009491A (es) 2017-01-13

Family

ID=53682019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009491A MX2016009491A (es) 2014-01-27 2015-01-26 Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.

Country Status (12)

Country Link
US (1) US20160363591A1 (es)
EP (2) EP3099323A4 (es)
JP (1) JP2017509692A (es)
KR (1) KR20160113700A (es)
CN (1) CN105934254A (es)
AU (1) AU2015209124A1 (es)
BR (1) BR112016017192A2 (es)
CA (1) CA2937387A1 (es)
MX (1) MX2016009491A (es)
RU (1) RU2016134838A (es)
SG (1) SG11201606102UA (es)
WO (1) WO2015112970A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506064A (ja) * 2014-02-07 2017-03-02 メディミューン，エルエルシー ヒトペリオスチンを検出する新規アッセイ
WO2016112261A2 (en) 2015-01-09 2016-07-14 Medimmune, Llc Assay to detect human dpp-4
HK1255922A1 (zh) * 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作為嗜酸性粒細胞疾病中嗜酸性粒細胞靶向治療藥物臨床反應的預測因子
FI3448391T3 (fi) 2016-04-27 2024-06-19 Abbvie Mfg Management Unlimited Company Sellaisten sairauksien hoitomenetelmät, joissa IL-13-aktiviteetti on haitallinen, käyttämällä anti-IL-13-vasta-aineita
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
SG11201900845YA (en) * 2016-09-23 2019-02-27 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis
CA3049847A1 (en) 2017-02-24 2018-08-30 Trustees Of Boston University Isolation of human lung progenitors derived from pluripotent stem cells
CN109055522A (zh) * 2018-07-03 2018-12-21 吉林大学 C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用
EP3878868B1 (en) * 2018-11-09 2024-10-09 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN113155996A (zh) * 2021-03-23 2021-07-23 广州医科大学附属第一医院（广州呼吸中心） 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP1631680A2 (en) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
US8142994B2 (en) * 2004-02-23 2012-03-27 Erasmus University Medical Center Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
WO2008091814A2 (en) * 2007-01-22 2008-07-31 Wyeth Assessment of asthma and allergen-dependent gene expression
WO2008097198A1 (en) * 2007-02-09 2008-08-14 Agency For Science, Technology And Research Apparatus and method for analysis of data traffic
EP2644711B1 (en) * 2007-10-23 2018-07-04 Clinical Genomics Pty Ltd A method of diagnosing neoplasms - II
EP2271770B1 (en) 2008-03-31 2018-08-22 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
NO2627673T3 (es) * 2010-10-15 2017-12-23
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS

Also Published As

Publication number Publication date
RU2016134838A3 (es) 2018-09-27
CN105934254A (zh) 2016-09-07
KR20160113700A (ko) 2016-09-30
BR112016017192A2 (pt) 2017-10-10
EP3099323A4 (en) 2017-10-04
WO2015112970A1 (en) 2015-07-30
EP3099323A1 (en) 2016-12-07
JP2017509692A (ja) 2017-04-06
SG11201606102UA (en) 2016-08-30
RU2016134838A (ru) 2018-03-07
US20160363591A1 (en) 2016-12-15
EP3685857A1 (en) 2020-07-29
CA2937387A1 (en) 2015-07-30
AU2015209124A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
MX2016009491A (es) Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.
HK1255922A1 (zh) 二肽基肽酶-4和骨膜素作為嗜酸性粒細胞疾病中嗜酸性粒細胞靶向治療藥物臨床反應的預測因子
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
WO2015169966A3 (en) Methods for treating inflammatory bowel disease
MX2016002879A (es) Sistemas, dispositivos y metodos para la terapia anti-tl1a.
NZ602618A (en) Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
AR084831A1 (es) Terapia anticancer mediante inhibidores de quinasa
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
WO2010118243A3 (en) Use of il-27 antagonists to treat lupus
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
MX2018007589A (es) Ccl20 como indicador de respuesta clinica a antagonistas de il23.
IN2014DN08537A (es)
WO2011128820A8 (en) Methods for the analysis of breast cancer disorders
WO2013063062A3 (en) Il-19 as a biomarker of tslp treatment
HK1229236A1 (en) Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
UA116615C2 (uk) Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy
WO2011156000A3 (en) Use of il-4/il-13 antagonists to treat eosinophilic disorders
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
BR112014027413A2 (pt) biomarcadores para terapia com inibidor de iap
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.